Tag: PSA Screening

Prostate MRI versus PSA Screening for Prostate Cancer Detection (the MVP Study): A Randomised Clinical Trial

This 2023 randomized clinical trial (MVP Study) evaluated the comparative effectiveness of MRI versus prostate-specific antigen (PSA) screening in prostate cancer detection. The study included men aged 50–75 and randomized them to receive either MRI or PSA screening. MRI screening demonstrated superior detection of clinically significant prostate cancers (Gleason score

Read More »

Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence

This review evaluates the benefits and risks associated with prostate-specific antigen (PSA) screening for prostate cancer. Evidence indicates that PSA screening may reduce prostate cancer-specific mortality, but it also carries significant risks, including overdiagnosis and overtreatment. The review recommends that clinicians engage in shared decision-making with average-risk men aged 55

Read More »